Collaboration in Oncology


To eliminate cancer as a cause of death, we understand that we cannot work alone. Improving patient outcomes in lung, ovarian, breast, and haematological cancer requires a collaborative approach to research and development, and AstraZeneca is committed to working alongside other organisations to bring life-changing medicines to patients in need.

In lung cancer, for example, we have brought together complementary expertise to aid discovery and accelerate development in new medicines through a variety of partnerships and initiatives:

  • Sponsorship of the US Lung Master Protocol (LUNG-MAP) trial, a multi-drug, multi-arm biomarker-driven clinical trial in patients with advanced squamous cell lung cancer and a collaboration between the National Cancer Institute, pharmaceutical companies, and multiple research organisations
  • Alliance with Cancer Research UK (CRUK) on the Stratified Medicines Programme
  • Establishing of the CRUK-MEDI Alliance Laboratory, a collaboration between MedImmune, our biologics unit, and Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, to develop new biologic cancer medicines, a first-of-its kind partnership for CRT
  • Partnering with Genomics England, a public-private consortium, to accelerate development of new diagnostics treatments arising from the 100,000 Genomes Project

We are also early adopters of new technologies to support innovation, including:

  • CRISPR, innovative genome editing techniques, academic research collaborations in the US and UK
  • A next-generation sequencing platform for companion diagnostics in oncology via our collaboration with Illumina, Inc.
  • A companion circulating tumour DNA (ctDNA) diagnostic test for use with Iressa, developed as part of our long-standing partnership with Netherlands-based Qiagen